The economic costs of heroin addiction in the United States.
paper
Cited
Public
Unavailable
- Authors
- Mark, T L; Woody, G E; Juday, T; Kleber, H D
- Year
- 2001
- Journal
- Drug and alcohol dependence
- PMID
- 11137285
- DOI
- 10.1016/s0376-8716(00)00162-9
This study documents the costs of heroin addiction in the United States, both to the addict and society at large. Using a cost-of-illness approach, costs were estimated in four broad areas: medical care, lost productivity, crime, and social welfare. We estimate that the cost of heroin addiction in the United States was US$21.9 billion in 1996. Of these costs, productivity losses accounted for approximately US$11.5 billion (53%), criminal activities US$5.2 billion (24%), medical care US$5.0 billion (23%), and social welfare US$0.1 billion (0.5%). The large economic burden resulting from heroin addiction highlights the importance of investment in prevention and treatment.
No figures extracted from this document.
No chunks โ full text not yet ingested.
No entities extracted from this document yet.
No uploaded files.
Not in any collection.
No citations found.
In this knowledge base
External
| Title | Authors | Journal | Year | Link |
|---|---|---|---|---|
| Association of federal poverty level with healthcare expenditures among opioids users in the United States (2008-2019): a serial cross-sectional study. | Bounthavong M et al. | โ | 2025 | โ |
| Identification of Retention in Oxford Houses and Other Types of Recovery Housing: A Scoping Review. | Ellis J et al. | โ | 2025 | โ |
| Budget impact tool for the incorporation of medications for opioid use disorder into jail/prison facilities. | Ryan DA et al. | โ | 2023 | โ |
| CaMKII regulates the proteins TPM1 and MYOM2 and promotes diacetylmorphine-induced abnormal cardiac rhythms. | Ji M et al. | โ | 2023 | โ |
| Determinants of health-related quality of life among individuals with opioid use disorder, recently released from incarceration. | Cadet T et al. | โ | 2023 | โ |
| Direct Medical Cost of Treating Substance Use Disorders in Two Tertiary Hospitals in South-West, Nigeria: A Cross-Sectional Study. | Ilomuanya M et al. | โ | 2022 | โ |
| Impact of Transcranial Direct Current Stimulation on Ultra-Rapid Opioid Detoxification Outcome. | Mirhosseini H et al. | โ | 2022 | โ |
| A Novel Maintenance Therapeutic for Opioid Use Disorder. | Youngblood B et al. | โ | 2021 | โ |
| Cost-effectiveness implications of increasing the efficiency of the extended-release naltrexone induction process for the treatment of opioid use disorder: a secondary analysis. | Murphy SM et al. | โ | 2021 | โ |
| Factors That Affect Patient Attrition in Buprenorphine Treatment for Opioid Use Disorder: A Retrospective Real-World Study Using Electronic Health Records. | Ker S et al. | โ | 2021 | โ |
| Female rats express heroin-induced and -conditioned suppression of peripheral nitric oxide production in response to endotoxin challenge. | Paniccia JE et al. | โ | 2021 | โ |
| Massachusetts Justice Community Opioid Innovation Network (MassJCOIN). | Evans EA et al. | โ | 2021 | โ |
| The association of prefrontal cortex response during a natural reward cue-reactivity paradigm, anhedonia, and demoralization in persons maintained on methadone. | Huhn AS et al. | โ | 2021 | โ |
| Cost-effectiveness analysis of a large jail-based methadone maintenance treatment continuation program in New Mexico. | Horn BP et al. | โ | 2020 | โ |
| Depression and Outcomes of Methadone and Buprenorphine Treatment Among People with Opioid Use Disorders: A Literature Review. | Ghabrash MF et al. | โ | 2020 | โ |
| Fifteen years of heroin-assisted treatment in a Swiss prison-a retrospective cohort study. | Liebrenz M et al. | โ | 2020 | โ |
| Health and economic outcomes of treatment with extended-release naltrexone among pre-release prisoners with opioid use disorder (HOPPER): protocol for an evaluation of two randomized effectiveness trials. | Murphy SM et al. | โ | 2020 | โ |
| Prison sentencing increases the risk of unemployment among illegal heroin users in Taiwan. | Lee CT et al. | โ | 2020 | โ |
| Sulfonate-isosteric replacement examined within heroin-hapten vaccine design. | Belz TF et al. | โ | 2020 | โ |
| What Is the Financial Impact of Orthopaedic Sequelae of Intravenous Drug Use on Urban Tertiary-care Centers? | Dwivedi N et al. | โ | 2020 | โ |
| Admitted to treatment without diagnosis: The status of known diagnoses in US addictions treatment centres. | Sahker E et al. | โ | 2019 | โ |
| Cost-Effectiveness of Buprenorphine-Naloxone Versus Extended-Release Naltrexone to Prevent Opioid Relapse. | Murphy SM et al. | โ | 2019 | โ |
| Defining the Correlation Between Heroin Overdose and Length of Hospital Admissions. | Reinert J et al. | โ | 2019 | โ |
| Homelessness among immigrants in the United States: rates, correlates, and differences compared with native-born adults. | Tsai J et al. | โ | 2019 | โ |
| The Association between Living Status Transitions, Behavior Changes and Family Relationship Improvement among Methadone Maintenance Treatment Participants in Guangdong, China. | Liu S et al. | โ | 2019 | โ |
| The mediating and moderating effects of resilience on the relationship between perceived stress and depression in heroin addicts. | Wang L et al. | โ | 2019 | โ |
| Altered gray matter volume and disrupted functional connectivity of dorsolateral prefrontal cortex in men with heroin dependence. | Lin HC et al. | โ | 2018 | โ |
| Health-related work productivity loss is low for patients in a methadone maintenance program in Vietnam. | Tran BX et al. | โ | 2018 | โ |
| Predictors of sleep disturbance in heroin users receiving methadone maintenance therapy: a naturalistic study in Taiwan. | Li DJ et al. | โ | 2018 | โ |
| Prevalence, Diagnosis, and Treatment Rates of Mood Disorders among Opioid Users under Criminal Justice Supervision. | Mbaba M et al. | โ | 2018 | โ |
| When is coercive methadone therapy justified? | D'Hotman D et al. | โ | 2018 | โ |
| Buprenorphine for managing opioid withdrawal. | Gowing L et al. | โ | 2017 | โ |
| Cost-effectiveness of extended release naltrexone to prevent relapse among criminal justice-involved individuals with a history of opioid use disorder. | Murphy SM et al. | โ | 2017 | โ |
| Costs of substance use disorders from claims data for Medicare recipients from a population-based sample. | Fairman BJ et al. | โ | 2017 | โ |
| Development of a Clinically Viable Heroin Vaccine. | Bremer PT et al. | โ | 2017 | โ |
| Differential expression of endocannabinoid system-related genes in the dorsal hippocampus following expression and reinstatement of morphine conditioned place preference in mice. | Li W et al. | โ | 2017 | โ |
| Effects of environmental enrichment on self-administration of the short-acting opioid remifentanil in male rats. | Hofford RS et al. | โ | 2017 | โ |
| Opioid antagonists with minimal sedation for opioid withdrawal. | Gowing L et al. | โ | 2017 | โ |
| Perceived need for depression treatment among persons entering inpatient opioid detoxification. | Stein MD et al. | โ | 2017 | โ |
| Pilot Studies Examining Feasibility of Substance Use Disorder Screening and Treatment Linkage at Urban Sexually Transmitted Disease Clinics. | Gryczynski J et al. | โ | 2017 | โ |
| Relationship Themes Present between Parents and Children in Recovery Homes. | Isler B et al. | โ | 2017 | โ |
| Sociodemographic and access-related correlates of health-care utilization among African American injection drug users: The BESURE study. | Maragh-Bass AC et al. | โ | 2017 | โ |
| The societal cost of heroin use disorder in the United States. | Jiang R et al. | โ | 2017 | โ |
| Young people who use drugs engaged in harm reduction programs in New York City: Overdose and other risks. | Calvo M et al. | โ | 2017 | โ |
| Acquisition of heroin conditioned immunosuppression requires IL-1 signaling in the dorsal hippocampus. | Lebonville CL et al. | โ | 2016 | โ |
| Alphaโ-adrenergic agonists for the management of opioid withdrawal. | Gowing L et al. | โ | 2016 | โ |
| An integrated model of depression, compulsion, and mindfulness among heroin abusers in Taiwan. | Lee KH et al. | โ | 2016 | โ |
| Economic Evaluations of Opioid Use Disorder Interventions. | Murphy SM et al. | โ | 2016 | โ |
| Factors associated with non-adherence to Buprenorphine-naloxone among opioid dependent African-Americans: A retrospective chart review. | Kumari S et al. | โ | 2016 | โ |
| Genome-Wide Pharmacogenomic Study on Methadone Maintenance Treatment Identifies SNP rs17180299 and Multiple Haplotypes on CYP2B6, SPON1, and GSG1L Associated with Plasma Concentrations of Methadone R- and S-enantiomers in Heroin-Dependent Patients. | Yang HC et al. | โ | 2016 | โ |
| Pharmacotherapy for opioid dependence in jails and prisons: research review update and future directions. | Sharma A et al. | โ | 2016 | โ |
| Treatment utilization among persons with opioid use disorder in the United States. | Wu LT et al. | โ | 2016 | โ |
| Association between Blood Level of Plasma Oxytocin and Novelty Seeking among Methadone-Maintained Heroin Users. | Lin SH et al. | โ | 2015 | โ |
| Comparing the life concerns of prescription opioid and heroin users. | Stein MD et al. | โ | 2015 | โ |
| Comparison of adverse obstetric outcomes and maternity hospitalization among heroin-exposed and methadone-treated women in Taiwan. | Chen CY et al. | โ | 2015 | โ |
| Cost-Effectiveness of Injectable Extended-Release Naltrexone Compared With Methadone Maintenance and Buprenorphine Maintenance Treatment for Opioid Dependence. | Jackson H et al. | โ | 2015 | โ |
| Cost-of-illness studies for bipolar disorder: systematic review of international studies. | Jin H et al. | โ | 2015 | โ |
| Hurdles that impede economic evaluations of welfare interventions. | Schepers J et al. | โ | 2015 | โ |
| Income Generation in Recovering Heroin Users: A Comparative Analysis of Legal and Illegal Earnings. | Callahan S et al. | โ | 2015 | โ |
| Opioid misuse among adolescents: new evidence from a misclassification analysis. | Murphy SM et al. | โ | 2015 | โ |
| Potential radiating effects of misusing substances among medical patients receiving brief intervention. | Gryczynski J et al. | โ | 2015 | โ |
| Predictors of buprenorphine initial outpatient maintenance and dose taper response among non-treatment-seeking heroin dependent volunteers. | Woodcock EA et al. | โ | 2015 | โ |
| Replication of ZNF804A gene variant associations with risk of heroin addiction. | Hancock DB et al. | โ | 2015 | โ |
| The CHANGE Study: Methods and Sample Description for a Cross-Sectional Study of Heroin Cessation in New York City. | Ompad DC et al. | โ | 2015 | โ |
| The reductions in monetary cost and gains in productivity with methadone maintenance treatment: one year follow-up. | Hsiao CY et al. | โ | 2015 | โ |
| The Supply of Physicians Waivered to Prescribe Buprenorphine for Opioid Use Disorders in the United States: A State-Level Analysis. | Knudsen HK | โ | 2015 | โ |
| Association analysis of GABRB3 promoter variants with heroin dependence. | Chen CH et al. | โ | 2014 | โ |
| Costs of care for persons with opioid dependence in commercial integrated health systems. | Lynch FL et al. | โ | 2014 | โ |
| Craving predicts opioid use in opioid-dependent patients initiating buprenorphine treatment: a longitudinal study. | Tsui JI et al. | โ | 2014 | โ |
| Determinants of buprenorphine treatment for opioid dependence. | Murphy SM et al. | โ | 2014 | โ |
| Factors affecting noncompliance with buprenorphine maintenance treatment. | Fareed A et al. | โ | 2014 | โ |
| Impact of research network participation on the adoption of buprenorphine for substance abuse treatment. | Rieckmann TR et al. | โ | 2014 | โ |
| [Injectable extended-release naltrexone for the prevention of relapse to opioid dependence following opioid detoxification]. | Krupitskiฤญ EM | โ | 2014 | โ |
| Injection route and TLR9 agonist addition significantly impact heroin vaccine efficacy. | Bremer PT et al. | โ | 2014 | โ |
| Looking for the uninsured in Massachusetts? Check opioid dependent persons seeking detoxification. | Stein MD et al. | โ | 2014 | โ |
| Mobile opioid agonist treatment and public funding expands treatment for disenfranchised opioid-dependent individuals. | Hall G et al. | โ | 2014 | โ |
| Practical guide to the management of acute and chronic pain in the presence of drug tolerance for the healthcare practitioner. | Vadivelu N et al. | โ | 2014 | โ |
| Tests of data quality, scaling assumptions, reliability, and construct validity of the SF-36 health survey in people who abuse heroin. | Chiu EC et al. | โ | 2014 | โ |
| Associations among hypothalamus-pituitary-adrenal axis function, novelty seeking, and retention in methadone maintenance therapy for heroin dependency. | Lin SH et al. | โ | 2013 | โ |
| Buprenorphine from detox and beyond: preliminary evaluation of a pilot program to increase heroin dependent individuals' engagement in a full continuum of care. | Donovan DM et al. | โ | 2013 | โ |
| Cannabinoid and opioid interactions: implications for opiate dependence and withdrawal. | Scavone JL et al. | โ | 2013 | โ |
| Disparities in access to physicians and medications for the treatment of substance use disorders between publicly and privately funded treatment programs in the United States. | Abraham AJ et al. | โ | 2013 | โ |
| Employment-based reinforcement of adherence to oral naltrexone treatment in unemployed injection drug users. | Dunn KE et al. | โ | 2013 | โ |
| Exercise as an adjuvant intervention in opiate dependence. | Pareja-Galeano H et al. | โ | 2013 | โ |
| Predictors for dropping-out from methadone maintenance therapy programs among heroin users in southern Taiwan. | Lin HC et al. | โ | 2013 | โ |
| Psychiatric and medical comorbidities, associated pain, and health care utilization of patients prescribed buprenorphine. | Mark TL et al. | โ | 2013 | โ |
| Suboxone misuse along the opiate maintenance treatment pathway. | Furst RT | โ | 2013 | โ |
| The economic cost of heroin dependency and quality of life among heroin users in Taiwan. | Lin SH et al. | โ | 2013 | โ |
| Trends in opioid agonist therapy in the Veterans Health Administration: is supply keeping up with demand? | Oliva EM et al. | โ | 2013 | โ |
| A comparison of suboxone and clonidine treatment outcomes in opiate detoxification. | Steele A et al. | โ | 2012 | โ |
| A randomized trial of methadone initiation prior to release from incarceration. | McKenzie M et al. | โ | 2012 | โ |
| Availability of dopamine and serotonin transporters in opioid-dependent users--a two-isotope SPECT study. | Yeh TL et al. | โ | 2012 | โ |
| Budgetary impact analysis of buprenorphine-naloxone combination (Suboxoneยฎ) in Spain. | Martinez-Raga J et al. | โ | 2012 | โ |
| Cost effectiveness of screening strategies for early identification of HIV and HCV infection in injection drug users. | Cipriano LE et al. | โ | 2012 | โ |
| Exercise as an adjunct treatment for opiate agonist treatment: review of the current research and implementation strategies. | Weinstock J et al. | โ | 2012 | โ |
| Investigating the effects of a hydrolytically stable hapten and a Th1 adjuvant on heroin vaccine performance. | Bremer PT et al. | โ | 2012 | โ |
| Latent classes of heroin and cocaine users predict unique HIV/HCV risk factors. | Harrell PT et al. | โ | 2012 | โ |
| Love and addiction: the devil is in the differences: a commentary on "the behavioral, anatomical and pharmacological parallels between social attachment, love and addiction". | Hostetler CM et al. | โ | 2012 | โ |
| Vaccines against drug abuse. | Shen XY et al. | โ | 2012 | โ |
| A multi-level analysis of counselor attitudes toward the use of buprenorphine in substance abuse treatment. | Rieckmann TR et al. | โ | 2011 | โ |
| Anti-addiction vaccines. | Shen X et al. | โ | 2011 | โ |
| A vaccine strategy that induces protective immunity against heroin. | Stowe GN et al. | โ | 2011 | โ |
| Developing a vaccine against multiple psychoactive targets: a case study of heroin. | Stowe GN et al. | โ | 2011 | โ |
| Factors associated with Medicaid patients' access to buprenorphine treatment. | Baxter JD et al. | โ | 2011 | โ |
| Heroin use, dependence, and attitudes to treatment in non-treatment-seeking heroin users: a pilot study. | Dean AJ et al. | โ | 2011 | โ |
| Induction of opioid-dependent individuals onto buprenorphine and buprenorphine/naloxone soluble-films. | Strain EC et al. | โ | 2011 | โ |
| Opioid dependence. | Benich JJ | โ | 2011 | โ |
| Patterns in admission delays to outpatient methadone treatment in the United States. | Gryczynski J et al. | โ | 2011 | โ |
| Adoption of medications in substance abuse treatment: priorities and strategies of single state authorities. | Rieckmann T et al. | โ | 2010 | โ |
| Antidepressant treatment does not improve buprenorphine retention among opioid-dependent persons. | Stein MD et al. | โ | 2010 | โ |
| A review of opioid dependence treatment: pharmacological and psychosocial interventions to treat opioid addiction. | Veilleux JC et al. | โ | 2010 | โ |
| Dissolution of a harm reduction track for opiate agonist treatment: longitudinal impact on treatment retention, substance use and service utilization. | Hartzler B et al. | โ | 2010 | โ |
| Obstructive sleep apnea is more common than central sleep apnea in methadone maintenance patients with subjective sleep complaints. | Sharkey KM et al. | โ | 2010 | โ |
| Opioid antagonists under heavy sedation or anaesthesia for opioid withdrawal. | Gowing L et al. | โ | 2010 | โ |
| Organizational issues in the implementation of a hospital-based syringe exchange program. | Masson CL et al. | โ | 2010 | โ |
| Service use and barriers to care among heroin users: results from a national survey. | Mowbray O et al. | โ | 2010 | โ |
| Substance abuse and rehabilitation: responding to the global burden of diseases attributable to substance abuse. | Wu LT | โ | 2010 | โ |
| The cost of concordance with opiate substitution treatment guidelines. | Barnett PG et al. | โ | 2010 | โ |
| The impact of financial discharge from methadone maintenance therapy on incarceration. | Zaller ND et al. | โ | 2010 | โ |
| Using administrative data for longitudinal substance abuse research. | Evans E et al. | โ | 2010 | โ |
| Using buprenorphine to treat opioid-dependent university students: opportunities, successes, and challenges. | Demaria PA et al. | โ | 2010 | โ |
| What economics can contribute to the addiction sciences. | Caulkins JP et al. | โ | 2010 | โ |
| Why don't out-of-treatment individuals enter methadone treatment programmes? | Peterson JA et al. | โ | 2010 | โ |
| An economic analysis of income and expenditures by heroin-using research volunteers. | Roddy J et al. | โ | 2009 | โ |
| A randomized clinical trial of methadone maintenance for prisoners: results at 12 months postrelease. | Kinlock TW et al. | โ | 2009 | โ |
| A social network perspective on heroin and cocaine use among adults: evidence of bidirectional influences. | Bohnert AS et al. | โ | 2009 | โ |
| Cost analysis of clinic and office-based treatment of opioid dependence: results with methadone and buprenorphine in clinically stable patients. | Jones ES et al. | โ | 2009 | โ |
| Home polysomnography in methadone maintenance patients with subjective sleep complaints. | Sharkey KM et al. | โ | 2009 | โ |
| Opioid antagonists with minimal sedation for opioid withdrawal. | Gowing L et al. | โ | 2009 | โ |
| Promoting abstinence from cocaine and heroin with a methadone dose increase and a novel contingency. | Epstein DH et al. | โ | 2009 | โ |
| Urine and plasma pharmacokinetics of lofexidine after oral delivery in opiate-dependent patients. | Al Ghananeem AM et al. | โ | 2009 | โ |
| A 50-year-old woman addicted to heroin: review of treatment of heroin addiction. | O'Brien CP | โ | 2008 | โ |
| A randomized clinical trial of methadone maintenance for prisoners: findings at 6 months post-release. | Gordon MS et al. | โ | 2008 | โ |
| A Study of Methadone Maintenance For Male Prisoners: 3-Month Postrelease Outcomes. | Kinlock TW et al. | โ | 2008 | โ |
| A unified framework for addiction: vulnerabilities in the decision process. | Redish AD et al. | โ | 2008 | โ |
| Economic evaluation of interventions to treat opiate dependence : a review of the evidence. | Doran CM | โ | 2008 | โ |
| EEG biofeedback as a treatment for substance use disorders: review, rating of efficacy, and recommendations for further research. | Sokhadze TM et al. | โ | 2008 | โ |
| Prediction of abstinence in opioid-dependent patients. | Dijkstra BA et al. | โ | 2008 | โ |
| The incremental inpatient costs associated with marijuana comorbidity. | Pacula RL et al. | โ | 2008 | โ |
| A randomized clinical trial of methadone maintenance for prisoners: results at 1-month post-release. | Kinlock TW et al. | โ | 2007 | โ |
| Disordered eating behaviors and substance use in women: a comparison of perceived adverse consequences. | Piran N et al. | โ | 2007 | โ |
| Heroin-assisted treatment (HAT) a decade later: a brief update on science and politics. | Fischer B et al. | โ | 2007 | โ |
| Implementation of buprenorphine in the Veterans Health Administration: results of the first 3 years. | Gordon AJ et al. | โ | 2007 | โ |
| Increased response to morphine in mice lacking protein kinase C epsilon. | Newton PM et al. | โ | 2007 | โ |
| Intravenous and intranasal heroin-dependent treatment-seekers: characteristics and treatment outcome. | Highfield DA et al. | โ | 2007 | โ |
| Managing addiction as a chronic condition. | Dennis M et al. | โ | 2007 | โ |
| Process improvement needs in substance abuse treatment: admissions walk-through results. | Ford JH et al. | โ | 2007 | โ |
| Research network involvement and addiction treatment center staff: counselor attitudes toward buprenorphine. | Knudsen HK et al. | โ | 2007 | โ |
| Sustained-release naltrexone: novel treatment for opioid dependence. | Comer SD et al. | โ | 2007 | โ |
| The adoption of medications in substance abuse treatment: associations with organizational characteristics and technology clusters. | Knudsen HK et al. | โ | 2007 | โ |
| Willingness to pay for drug abuse treatment: results from a contingent valuation study in Taiwan. | Tang CH et al. | โ | 2007 | โ |
| Benefit-cost in the California treatment outcome project: does substance abuse treatment "pay for itself"? | Ettner SL et al. | โ | 2006 | โ |
| Buprenorphine for the management of opioid withdrawal. | Gowing L et al. | โ | 2006 | โ |
| Cost-of-illness studies : a review of current methods. | Akobundu E et al. | โ | 2006 | โ |
| Estimated costs of prescription opioid analgesic abuse in the United States in 2001: a societal perspective. | Birnbaum HG et al. | โ | 2006 | โ |
| How cost-of-illness studies can be made more useful for illicit drug policy analysis. | Moore TJ et al. | โ | 2006 | โ |
| Linking opioid-dependent hospital patients to drug treatment: Health care use and costs 6 months after randomization. | Barnett PG et al. | โ | 2006 | โ |
| Pharmaco-economics of community maintenance for opiate dependence: a review of evidence and methodology. | Simoens S et al. | โ | 2006 | โ |
| The zebrafish as a model system for assessing the reinforcing properties of drugs of abuse. | Ninkovic J et al. | โ | 2006 | โ |
| Buprenorphine diffusion: the attitudes of substance abuse treatment counselors. | Knudsen HK et al. | โ | 2005 | โ |
| Buprenorphine retention in primary care. | Stein MD et al. | โ | 2005 | โ |
| Challenges in the adoption of new pharmacotherapeutics for addiction to alcohol and other drugs. | Saxon AJ et al. | โ | 2005 | โ |
| Impact of Federal drug law enforcement on the supply of heroin in Australia. | Smithson M et al. | โ | 2005 | โ |
| Modeling the economic burden of diseases imputable to stress at work. | Bรฉjean S et al. | โ | 2005 | โ |
| The effectiveness of community maintenance with methadone or buprenorphine for treating opiate dependence. | Simoens S et al. | โ | 2005 | โ |
| Using [11C]diprenorphine to image opioid receptor occupancy by methadone in opioid addiction: clinical and preclinical studies. | Melichar JK et al. | โ | 2005 | โ |
| Alpha2 adrenergic agonists for the management of opioid withdrawal. | Gowing L et al. | โ | 2004 | โ |
| Buprenorphine: a primer for emergency physicians. | Sporer KA | โ | 2004 | โ |
| Effectiveness of interventions on opiate withdrawal treatment: an overview of systematic reviews. | Amato L et al. | โ | 2004 | โ |
| Opiate state controls bi-directional reward signaling via GABAA receptors in the ventral tegmental area. | Laviolette SR et al. | โ | 2004 | โ |
| Behavioral family counseling and naltrexone for male opioid-dependent patients. | Fals-Stewart W et al. | โ | 2003 | โ |
| Type and location of injection drug use-related soft tissue infections predict hospitalization. | Takahashi TA et al. | โ | 2003 | โ |
| Abstinence reinforcement maintenance contingency and one-year follow-up. | Preston KL et al. | โ | 2002 | โ |
| Drug addictions: towards socially accepted and medically treatable diseases. | Pouletty P | โ | 2002 | โ |
| Lack of reward and locomotor stimulation induced by heroin in mu-opioid receptor-deficient mice. | Contarino A et al. | โ | 2002 | โ |
| Pharmacotherapy of addictions. | Kreek MJ et al. | โ | 2002 | โ |
| Policy progress for physician treatment of opiate addiction. | Merrill JO | โ | 2002 | โ |
| Behavioral screening for cocaine sensitivity in mutagenized zebrafish. | Darland T et al. | โ | 2001 | โ |
| Office-based treatment for opioid dependence: reaching new patient populations. | Fiellin DA et al. | โ | 2001 | โ |